The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
HER‐2 pulsed dendritic cell vaccine can eliminate HER‐2 expression and impact ductal carcinoma in situ
Open accessAbstract
BACKGROUND: HER‐2/neu overexpression plays a critical role in breast cancer development, and its expression in ductal carcinoma in situ (DCIS) is associated with development of invasive breast cancer. A vaccine targeting HER‐2/neu expression in DCIS may initiate immunity against invasive cancer. METHODS: A HER‐2/neu dendritic cell vaccine was administered to 27 patients with HER‐2/neu–overexpressing DCIS. The HER‐2/neu vaccine was administered before surgical resection, and pre‐ and postvaccination analysis was conducted to assess clinical results. RESULTS: At surgery, 5 of 27 (18.5%) vaccinated subjects had no evidence of remaining disease, whereas among 22 subjects with residual DCIS, HER‐2/neu expression was eradicated in 11 (50%). When comparing estrogen receptor (ER)neg with ER pos DCIS lesions, vaccination was more effective in hormone‐independent DCIS. After vaccination, no residual DCIS was found in 40% of ER neg subjects compared with 5.9% in ER pos subjects. Sustained HER‐2/neu expression was found in 10% of ER neg subjects compared with 47.1% in ER pos subjects (P = .04). Postvaccination phenotypes were significantly different between ER pos and ER neg subjects (P = .01), with 7 of 16 (43.8%) initially presenting with ER pos HER‐2/neupos luminal B phenotype finishing with the ER pos HER‐2/neuneg luminal A phenotype, and 3 of 6 (50%) with the ER neg HER‐2/neupos phenotype changing to the ER neg HER‐2/neuneg phenotype. CONCLUSIONS: Results suggest that vaccination against HER‐2/neu is safe and well tolerated and induces decline and/or eradication of HER‐2/neu expression. These findings warrant further exploration of HER‐2/neu vaccination in estrogen‐independent breast cancer and highlight the need to target additional tumor‐associated antigens and pathways. Cancer 2012. © 2012 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Overexpression of the c-erbB-2 protein in human breast tumor cell lines
Hynes, N. E., Gerber, H. A., Saurer, S., & Groner, B. (1989) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240390208 · Cited by 109
Cited by
Cancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Targeting HER2-positive breast cancer: advances and future directions
Swain, S. M., Shastry, M., & Hamilton, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00579-0 · Cited by 1,160
Dendritic cell-based immunotherapy
Sabado, R. L., Balan, S., & Bhardwaj, N. (2017) · Cell Research · doi:10.1038/cr.2016.157 · Cited by 927
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869
Metadata
- Authors
- Sharma, A., Koldovsky, U., Xu, S., Mick, R., Roses, R., Fitzpatrick, E., Weinstein, S., Nisenbaum, H., Levine, B. L., Fox, K., Zhang, P., Koski, G., & Czerniecki, B. J.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2012-01-17
- Volume
- 118
- Issue
- 17
- Pages
- 4354-4362
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1564805122
- Cited by
- 164
- References
- 2
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.